{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T13:03:17Z","timestamp":1789822997741,"version":"4.0.1"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:00:00Z","timestamp":1789776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:00:00Z","timestamp":1789776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020050","name":"Japan Intractable Diseases Research Foundation","doi-asserted-by":"publisher","award":["23FC1048"],"award-info":[{"award-number":["23FC1048"]}],"id":[{"id":"10.13039\/100020050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"DOI":"10.1007\/s10157-026-02944-4","type":"journal-article","created":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T10:56:12Z","timestamp":1789815372000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Systematic review and network meta-analysis for the 2026 update of the evidence-based clinical practice guidelines for the management with immunosuppressive therapies and biologic agents of membranous nephropathy"],"prefix":"10.1007","author":[{"given":"Reiji","family":"Takami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7365-7685","authenticated-orcid":false,"given":"Hiroki","family":"Nishiwaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Tsujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Oe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Onishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Oba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinnosuke","family":"Sugihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Miyaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Yazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Sofue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izaya","family":"Nakaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuji","family":"Ishimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiko","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriaki","family":"Kurita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayaka","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Furuichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiko","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,19]]},"reference":[{"issue":"7","key":"2944_CR1","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/s41581-022-00564-1","volume":"18","author":"E Hoxha","year":"2022","unstructured":"Hoxha E, Reinhard L, Stahl RAK. Membranous nephropathy: new pathogenic mechanisms and their clinical implications. Nat Rev Nephrol. 2022;18(7):466\u201378.","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"2944_CR2","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41572-021-00303-z","volume":"7","author":"P Ronco","year":"2021","unstructured":"Ronco P, Beck L, Debiec H, Fervenza FC, Hou FF, Jha V, et al. Membranous nephropathy. Nat Rev Dis Primers. 2021;7(1):69.","journal-title":"Nat Rev Dis Primers"},{"issue":"7650","key":"2944_CR3","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924\u20136.","journal-title":"BMJ"},{"issue":"12","key":"2944_CR4","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1007\/s10157-021-02098-5","volume":"25","author":"T Wada","year":"2020","unstructured":"Wada T, Ishimoto T, Nakaya I, Kawaguchi T, Sofue T, Shimizu S, et al. A digest of the evidence-based clinical practice guideline for nephrotic syndrome 2020. Clin Exp Nephrol. 2020;25(12):1277\u201385.","journal-title":"Clin Exp Nephrol"},{"issue":"11","key":"2944_CR5","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777\u201384.","journal-title":"Ann Intern Med"},{"issue":"1","key":"2944_CR6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","volume":"59","author":"TA Furukawa","year":"2006","unstructured":"Furukawa TA, Barbui C, Cipriani A, et al. Imputing missing standard deviations in meta-analyses can provide accurate results. J Clin Epidemiol. 2006;59(1):7\u201310.","journal-title":"J Clin Epidemiol"},{"key":"2944_CR7","unstructured":"Lefebvre C GJ, Briscoe S, Featherstone R, Littlewood A, Metzendorf M-I, et al. Chapter 4: Searching for and selecting studies [last updated September 2024]. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5. Cochrane, 2024. Available from: www.training.cochrane.org\/handbook."},{"issue":"1","key":"2944_CR8","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210.","journal-title":"Syst Rev"},{"key":"2944_CR9","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ (Clinical research ed). 2019;366:l4898.","journal-title":"BMJ (Clinical research ed)"},{"issue":"4","key":"2944_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003082","volume":"17","author":"A Nikolakopoulou","year":"2020","unstructured":"Nikolakopoulou A, Higgins JPT, Papakonstantinou T, Chaimani A, Del Giovane C, Egger M, et al. CINeMA: an approach for assessing confidence in the results of a network meta-analysis. PLoS Med. 2020;17(4):e1003082.","journal-title":"PLoS Med"},{"issue":"1","key":"2944_CR11","volume":"16","author":"T Papakonstantinou","year":"2020","unstructured":"Papakonstantinou T, Nikolakopoulou A, Higgins JPT, Egger M, Salanti G. CINeMA: Software for semiautomated assessment of the confidence in the results of network meta-analysis. Campbell Syst Rev. 2020;16(1):e1080.","journal-title":"Campbell Syst Rev"},{"issue":"5720","key":"2944_CR12","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1136\/bmj.3.5720.421","volume":"3","author":"DA Black","year":"1970","unstructured":"Black DA, Rose G, Brewer DB. Controlled trial of prednisone in adult patients with the nephrotic syndrome. Br Med J. 1970;3(5720):421\u20136.","journal-title":"Br Med J"},{"issue":"6","key":"2944_CR13","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/ki.1974.129","volume":"6","author":"JV Donadio","year":"1974","unstructured":"Donadio JV Jr, Holley KE, Anderson CF, Taylor WF. Controlled trial of cyclophosphamide in idiopathic membranous nephropathy. Kidney Int. 1974;6(6):431\u20139.","journal-title":"Kidney Int"},{"key":"2944_CR14","unstructured":"Controlled trial of azathioprine in the nephrotic syndrome secondary to idiopathic membranous glomerulonephritis. Can Med Assoc J. 1976;115(12):1209\u201310."},{"key":"2944_CR15","doi-asserted-by":"crossref","unstructured":"A controlled study of short-term prednisone treatment in adults with membranous nephropathy. Collaborative Study of the Adult Idiopathic Nephrotic Syndrome. N Engl J Med. 1979; 301(24):1301\u20136.","DOI":"10.1056\/NEJM197912133012401"},{"key":"2944_CR16","unstructured":"Imbasciati E, Cagnoli L, Case N, Pasquali S, Di Filippo G, Limido D, et al. [Controlled study of treatment of steroids and chlorambucil, in alternate months, for membranous nephropathy and focal glomerulosclerosis. Preliminary evaluation of the results]. Minerva Nefrol. 1980;27(4):571\u20135."},{"key":"2944_CR17","unstructured":"Tiller DJ CA, Mathew T, Thompson N, Row G, Lauer C, Hobbs J, Seymour A. A prospective randomized trial of cyclophosphamide, dipyridamole and warfarin in membranous and mesangiocapillary glomerulonephritis. Advances in Basic and Clinical Nephrology 8th International Congress of Nephrology; 1981 June 7\u201312; Athens, Greece: Basel: Karger; 1981. p. 345\u201351."},{"issue":"4","key":"2944_CR18","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1056\/NEJM198901263200403","volume":"320","author":"DC Cattran","year":"1989","unstructured":"Cattran DC, Delmore T, Roscoe J, Cole E, Cardella C, Charron R, et al. A randomized controlled trial of prednisone in patients with idiopathic membranous nephropathy. N Engl J Med. 1989;320(4):210\u20135.","journal-title":"N Engl J Med"},{"key":"2944_CR19","unstructured":"Majima K, Inoue T, Fukuda Y, Urae M, Ishizaki T, Kinoshita E, Nomura T. Effect of steroid therapy in patients with idiopathic membranous glomerulonephritis. Jpn J Nephrol. 1989;31(5):595. [Japanese] [Conference abstract]."},{"key":"2944_CR20","doi-asserted-by":"crossref","unstructured":"Cameron JS, Healy MJ, Adu D. The Medical Research Council trial of short-term high-dose alternate day prednisolone in idiopathic membranous nephropathy with nephrotic syndrome in adults. The MRC Glomerulonephritis Working Party. Q J Med. 1990;74(274):133\u201356.","DOI":"10.1093\/oxfordjournals.qjmed.a068422"},{"issue":"5","key":"2944_CR21","first-page":"229","volume":"37","author":"BF Murphy","year":"1992","unstructured":"Murphy BF, McDonald I, Fairley KF, Kincaid-Smith PS. Randomized controlled trial of cyclophosphamide, warfarin and dipyridamole in idiopathic membranous glomerulonephritis. Clin Nephrol. 1992;37(5):229\u201334.","journal-title":"Clin Nephrol"},{"issue":"9","key":"2944_CR22","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJM199208273270904","volume":"327","author":"C Ponticelli","year":"1992","unstructured":"Ponticelli C, Zucchelli P, Passerini P, Cesana B. Methylprednisolone plus chlorambucil as compared with methylprednisolone alone for the treatment of idiopathic membranous nephropathy. The Italian Idiopathic Membranous Nephropathy Treatment Study Group. N Engl J Med. 1992;327(9):599\u2013603.","journal-title":"N Engl J Med"},{"issue":"6","key":"2944_CR23","doi-asserted-by":"publisher","first-page":"438","DOI":"10.7326\/0003-4819-116-6-438","volume":"116","author":"RJ Falk","year":"1992","unstructured":"Falk RJ, Hogan SL, Muller KE, Jennette JC. Treatment of progressive membranous glomerulopathy. A randomized trial comparing cyclophosphamide and corticosteroids with corticosteroids alone. The Glomerular Disease Collaborative Network. Ann Intern Med. 1992;116(6):438\u201345.","journal-title":"Ann Intern Med"},{"issue":"6","key":"2944_CR24","first-page":"350","volume":"41","author":"DK Pahari","year":"1993","unstructured":"Pahari DK, Das S, Dutta BN, Banerjee D. Prognosis and management of membraneous nephropathy. J Assoc Physicians India. 1993;41(6):350\u20131.","journal-title":"J Assoc Physicians India"},{"key":"2944_CR25","unstructured":"Koshikawa S, Sato M, Narita M, Sakai O, Nakajima M. Clinical evaluation of an immunosuppressive drug, mizoribine (HE-69) on steroid-resistant nephrotic syndrome - A multicenter double-blind comparison study with placebo. Jin to Toseki. 1993;34(4). [Japanese]."},{"key":"2944_CR26","unstructured":"Ahmed S RM, Alam MR, Islam S, Chowdhury MN, Chowdhury SMZ, Chowdhury MAA. Methyl prednisolone plus chlorambucil as compared with prednisolone alone for the treatment of idiopathic membranous nephropathy - A preliminary study. Bangladesh renal journal. 1994;13(2)."},{"issue":"5","key":"2944_CR27","doi-asserted-by":"publisher","first-page":"328","DOI":"10.7326\/0003-4819-121-5-199409010-00003","volume":"121","author":"LJ Reichert","year":"1994","unstructured":"Reichert LJ, Huysmans FT, Assmann K, Koene RA, Wetzels JF. Preserving renal function in patients with membranous nephropathy: daily oral chlorambucil compared with intermittent monthly pulses of cyclophosphamide. Ann Intern Med. 1994;121(5):328\u201333.","journal-title":"Ann Intern Med"},{"issue":"4","key":"2944_CR28","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1038\/ki.1995.161","volume":"47","author":"DC Cattran","year":"1995","unstructured":"Cattran DC, Greenwood C, Ritchie S, Bernstein K, Churchill DN, Clark WF, et al. A controlled trial of cyclosporine in patients with progressive membranous nephropathy. Kidney Int. 1995;47(4):1130\u20135.","journal-title":"Kidney Int"},{"issue":"5","key":"2944_CR29","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1038\/ki.1995.453","volume":"48","author":"C Ponticelli","year":"1995","unstructured":"Ponticelli C, Zucchelli P, Passerini P, Cesana B, Locatelli F, Pasquali S, et al. A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int. 1995;48(5):1600\u20134.","journal-title":"Kidney Int"},{"issue":"3","key":"2944_CR30","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1681\/ASN.V93444","volume":"9","author":"C Ponticelli","year":"1998","unstructured":"Ponticelli C, Altieri P, Scolari F, Passerini P, Roccatello D, Cesana B, et al. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol. 1998;9(3):444\u201350.","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"2944_CR31","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1093\/qjmed\/91.5.359","volume":"91","author":"AJ Branten","year":"1998","unstructured":"Branten AJ, Reichert LJ, Koene RA, Wetzels JF. Oral cyclophosphamide versus chlorambucil in the treatment of patients with membranous nephropathy and renal insufficiency. QJM. 1998;91(5):359\u201366.","journal-title":"QJM"},{"issue":"4","key":"2944_CR32","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1046\/j.1523-1755.2001.0590041484.x","volume":"59","author":"DC Cattran","year":"2001","unstructured":"Cattran DC, Appel GB, Hebert LA, Hunsicker LG, Pohl MA, Hoy WE, et al. Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney Int. 2001;59(4):1484\u201390.","journal-title":"Kidney Int"},{"key":"2944_CR33","unstructured":"Dyadyk AI, Bagriy AE, Yarovaya NF, Dyadyk IA, State Medical University, Donetsk, Ucraine. Results of long-term randomized study of immunosuppressive treatment of patients with idiopatic membranous glomerulonephritis. Nephrology Dialysis Transplantation 2001; 16: A64"},{"key":"2944_CR34","unstructured":"Braun N DK, Vonthein R, Erley C, Risler T. Remission and relapses in idiopathic membranous nephropathy. Description by a longitudinal multi-state Markov-model. 41st Congress European Renal Association European Dialysis and Transplantation Association; 2004 May 15\u201318; Lisbon, Portugal; 2004. p. 34\u20135."},{"issue":"2","key":"2944_CR35","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s10157-004-0276-0","volume":"8","author":"T Shibasaki","year":"2004","unstructured":"Shibasaki T, Koyama A, Hishida A, Muso E, Osawa G, Yamabe H, et al. A randomized open-label comparative study of conventional therapy versus mizoribine onlay therapy in patients with steroid-resistant nephrotic syndrome (postmarketing survey). Clin Exp Nephrol. 2004;8(2):117\u201326.","journal-title":"Clin Exp Nephrol"},{"key":"2944_CR36","first-page":"571A","volume":"17","author":"M Arnadottir","year":"2006","unstructured":"Arnadottir M, Bergur S, Berg AL. A randomized study on treatment with adrenocorticotrophic hormone in idiopathic membranous nephropathy. J Am Soc Nephrol. 2006;17:571A.","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"2944_CR37","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1053\/j.ajkd.2005.10.016","volume":"47","author":"C Ponticelli","year":"2006","unstructured":"Ponticelli C, Passerini P, Salvadori M, Manno C, Viola BF, Pasquali S, et al. A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy. Am J Kidney Dis. 2006;47(2):233\u201340.","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"2944_CR38","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/sj.ki.5002215","volume":"71","author":"M Praga","year":"2007","unstructured":"Praga M, Barrio V, Juarez GF, Luno J, Grupo Espanol de Estudio de la Nefropatia M. Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial. Kidney Int. 2007;71(9):924\u201330.","journal-title":"Kidney Int"},{"issue":"6","key":"2944_CR39","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1111\/j.1440-1797.2007.00822.x","volume":"12","author":"TM Chan","year":"2007","unstructured":"Chan TM, Lin AW, Tang SC, Qian JQ, Lam MF, Ho YW, et al. Prospective controlled study on mycophenolate mofetil and prednisolone in the treatment of membranous nephropathy with nephrotic syndrome. Nephrology (Carlton). 2007;12(6):576\u201381.","journal-title":"Nephrology (Carlton)"},{"issue":"6","key":"2944_CR40","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1681\/ASN.2007020166","volume":"18","author":"V Jha","year":"2007","unstructured":"Jha V, Ganguli A, Saha TK, Kohli HS, Sud K, Gupta KL, et al. A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J Am Soc Nephrol. 2007;18(6):1899\u2013904.","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"2944_CR41","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1093\/ndt\/gfm538","volume":"23","author":"L Senthil Nayagam","year":"2008","unstructured":"Senthil Nayagam L, Ganguli A, Rathi M, Kohli HS, Gupta KL, Joshi K, et al. Mycophenolate mofetil or standard therapy for membranous nephropathy and focal segmental glomerulosclerosis: a pilot study. Nephrol Dial Transplant. 2008;23(6):1926\u201330.","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"2944_CR42","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1053\/j.ajkd.2008.04.013","volume":"52","author":"B Dussol","year":"2008","unstructured":"Dussol B, Morange S, Burtey S, Indreies M, Cassuto E, Mourad G, et al. Mycophenolate mofetil monotherapy in membranous nephropathy: a 1-year randomized controlled trial. Am J Kidney Dis. 2008;52(4):699\u2013705.","journal-title":"Am J Kidney Dis"},{"key":"2944_CR43","unstructured":"Oka H, Miishima N, Yoshitomi R, Mizobuchi T, Uemura T, Sugawara K, Harada A. Comparative study of combination therapy with cyclophosphamide versus mizoribine in patients with primary membranous nephropathy. Jpn J Nephrol. 2010;52:275. [Japanese] [Conference abstract]."},{"issue":"3","key":"2944_CR44","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1097\/MAJ.0b013e3181ca3a7d","volume":"339","author":"M Chen","year":"2010","unstructured":"Chen M, Li H, Li XY, Lu FM, Ni ZH, Xu FF, et al. Tacrolimus combined with corticosteroids in treatment of nephrotic idiopathic membranous nephropathy: a multicenter randomized controlled trial. Am J Med Sci. 2010;339(3):233\u20138.","journal-title":"Am J Med Sci"},{"issue":"5","key":"2944_CR45","doi-asserted-by":"publisher","first-page":"566","DOI":"10.3109\/08860221003728754","volume":"32","author":"G Kosmadakis","year":"2010","unstructured":"Kosmadakis G, Filiopoulos V, Smirloglou D, Skarlas P, Georgoulias C, Michail S. Comparison of immunosuppressive therapeutic regimens in patients with nephrotic syndrome due to idiopathic membranous nephropathy. Ren Fail. 2010;32(5):566\u201371.","journal-title":"Ren Fail"},{"issue":"2","key":"2944_CR46","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.biopha.2010.10.009","volume":"65","author":"R Naumovic","year":"2011","unstructured":"Naumovic R, Jovanovic D, Pavlovic S, Stosovic M, Marinkovic J, Basta-Jovanovic G. Cyclosporine versus azathioprine therapy in high-risk idiopathic membranous nephropathy patients: A 3-year prospective study. Biomed Pharmacother. 2011;65(2):105\u201310.","journal-title":"Biomed Pharmacother"},{"issue":"9868","key":"2944_CR47","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/S0140-6736(12)61566-9","volume":"381","author":"A Howman","year":"2013","unstructured":"Howman A, Chapman TL, Langdon MM, Ferguson C, Adu D, Feehally J, et al. Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial. Lancet. 2013;381(9868):744\u201351.","journal-title":"Lancet"},{"issue":"3","key":"2944_CR48","doi-asserted-by":"publisher","first-page":"564","DOI":"10.5301\/jn.5000199","volume":"26","author":"L He","year":"2013","unstructured":"He L, Peng Y, Liu H, Liu Y, Yuan S, Liu F, et al. Treatment of idiopathic membranous nephropathy with combination of low-dose tacrolimus and corticosteroids. J Nephrol. 2013;26(3):564\u201371.","journal-title":"J Nephrol"},{"key":"2944_CR49","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1159\/000348475","volume":"181","author":"J Xu","year":"2013","unstructured":"Xu J, Zhang W, Xu Y, Shen P, Ren H, Wang W, et al. Tacrolimus combined with corticosteroids in idiopathic membranous nephropathy: a randomized, prospective, controlled trial. Contrib Nephrol. 2013;181:152\u201362.","journal-title":"Contrib Nephrol"},{"key":"2944_CR50","doi-asserted-by":"crossref","unstructured":"S L. Clinical Trial of Treatment for Idiopathic Membranous Nephropathy with Leflunomide Combined with Cyclophosphamide and Glucocorticoid. Hong Kong Journal of Nephrology 2015;17.","DOI":"10.1016\/j.hkjn.2015.09.019"},{"issue":"2","key":"2944_CR51","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/nep.12569","volume":"21","author":"R Ramachandran","year":"2016","unstructured":"Ramachandran R, Hn HK, Kumar V, Nada R, Yadav AK, Goyal A, et al. Tacrolimus combined with corticosteroids versus Modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: Randomized control trial. Nephrology (Carlton). 2016;21(2):139\u201346.","journal-title":"Nephrology (Carlton)"},{"issue":"1","key":"2944_CR52","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jfma.2015.07.021","volume":"115","author":"L Peng","year":"2016","unstructured":"Peng L, Wei SY, Li LT, He YX, Li B. Comparison of different therapies in high-risk patients with idiopathic membranous nephropathy. J Formos Med Assoc. 2016;115(1):11\u20138.","journal-title":"J Formos Med Assoc"},{"issue":"1","key":"2944_CR53","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1681\/ASN.2016040449","volume":"28","author":"K Dahan","year":"2017","unstructured":"Dahan K, Debiec H, Plaisier E, Cachanado M, Rousseau A, Wakselman L, et al. Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up. J Am Soc Nephrol. 2017;28(1):348\u201358.","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"2944_CR54","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2018.33.e74","volume":"33","author":"JY Choi","year":"2018","unstructured":"Choi JY, Kim DK, Kim YW, Yoo TH, Lee JP, Chung HC, et al. The effect of mycophenolate mofetil versus cyclosporine as combination therapy with low dose corticosteroids in high-risk patients with idiopathic membranous nephropathy: a multicenter randomized trial. J Korean Med Sci. 2018;33(9):e74.","journal-title":"J Korean Med Sci"},{"issue":"1","key":"2944_CR55","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa1814427","volume":"381","author":"FC Fervenza","year":"2019","unstructured":"Fervenza FC, Appel GB, Barbour SJ, Rovin BH, Lafayette RA, Aslam N, et al. Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy. N Engl J Med. 2019;381(1):36\u201346.","journal-title":"N Engl J Med"},{"issue":"1","key":"2944_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-019-1539-z","volume":"20","author":"A Nikolopoulou","year":"2019","unstructured":"Nikolopoulou A, Condon M, Turner-Stokes T, Cook HT, Duncan N, Galliford JW, et al. Mycophenolate mofetil and tacrolimus versus tacrolimus alone for the treatment of idiopathic membranous glomerulonephritis: a randomised controlled trial. BMC Nephrol. 2019;20(1):352.","journal-title":"BMC Nephrol"},{"issue":"3","key":"2944_CR57","first-page":"1825","volume":"17","author":"WW Han","year":"2019","unstructured":"Han WW, Tang LJ, Kong XL, Yang H, Xu DM. Clinical significance of autoantibodies in the assessment and treatment of idiopathic membranous nephropathy. Exp Ther Med. 2019;17(3):1825\u201330.","journal-title":"Exp Ther Med"},{"issue":"1","key":"2944_CR58","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1080\/0886022X.2020.1713806","volume":"42","author":"Y Guo","year":"2020","unstructured":"Guo Y, Wu X, Liu L, Zhang H, Yang L, Chen W. Efficacy of leflunomide combined with prednisone for the treatment of PLA2R-associated primary membranous nephropathy. Ren Fail. 2020;42(1):122\u201330.","journal-title":"Ren Fail"},{"issue":"4","key":"2944_CR59","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1681\/ASN.2020071091","volume":"32","author":"F Scolari","year":"2021","unstructured":"Scolari F, Delbarba E, Santoro D, Gesualdo L, Pani A, Dallera N, et al. Rituximab or cyclophosphamide in the treatment of membranous nephropathy: the RI-CYCLO randomized trial. J Am Soc Nephrol. 2021;32(4):972\u201382.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"2944_CR60","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.kint.2020.10.014","volume":"99","author":"G Fernandez-Juarez","year":"2021","unstructured":"Fernandez-Juarez G, Rojas-Rivera J, Logt AV, Justino J, Sevillano A, Caravaca-Fontan F, et al. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy. Kidney Int. 2021;99(4):986\u201398.","journal-title":"Kidney Int"},{"issue":"4","key":"2944_CR61","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s11255-020-02680-y","volume":"53","author":"X Wang","year":"2021","unstructured":"Wang X, Zhang M, Zhang W, Liu Y, Han Y, Chang W. Effect of mizoribine pulse therapy in adult membranous nephropathy. Int Urol Nephrol. 2021;53(4):725\u201331.","journal-title":"Int Urol Nephrol"},{"issue":"1","key":"2944_CR62","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1093\/ndt\/gfad156","volume":"39","author":"Y Duan","year":"2023","unstructured":"Duan Y, Bai Y, Guo W, Wang L, Dai W, Guo W, et al. Multitarget therapy with a corticosteroid, cyclosporine and mycophenolate mofetil for idiopathic membranous nephropathy: a prospective randomized controlled trial. Nephrol Dial Transplant. 2023;39(1):95\u2013102.","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"2944_CR63","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s10157-022-02304-y","volume":"27","author":"X Wang","year":"2023","unstructured":"Wang X, Zhang M, Sun N, Chang W. Mizoribine combined with steroids and dietary sodium restriction on the treatment of primary membranous nephropathy: a prospective study. Clin Exp Nephrol. 2023;27(3):211\u20137.","journal-title":"Clin Exp Nephrol"},{"issue":"12","key":"2944_CR64","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1200\/JCO-24-02782","volume":"43","author":"HI Su","year":"2025","unstructured":"Su HI, Lacchetti C, Letourneau JM, et al. Fertility preservation in people with cancer: ASCO guideline update. J Clin Oncol. 2025;43(12):1488\u2013515.","journal-title":"J Clin Oncol"},{"issue":"12","key":"2944_CR65","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1200\/JCO.22.01885","volume":"41","author":"AC Reynolds","year":"2023","unstructured":"Reynolds AC, McKenzie LJ. Cancer treatment\u2013related ovarian dysfunction in women of childbearing potential: management and fertility preservation options. J Clin Oncol. 2023;41(12):2281\u201392.","journal-title":"J Clin Oncol"},{"issue":"9","key":"2944_CR66","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0184398","volume":"12","author":"S Ren","year":"2017","unstructured":"Ren S, Wang Y, Xian L, Toyama T, Jardine M, Li G, et al. Comparative effectiveness and tolerance of immunosuppressive treatments for idiopathic membranous nephropathy: a network meta-analysis. PLoS ONE. 2017;12(9):e0184398.","journal-title":"PLoS ONE"},{"issue":"4","key":"2944_CR67","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1007\/s40620-022-01268-2","volume":"35","author":"B Bose","year":"2022","unstructured":"Bose B, Chung EYM, Hong R, Strippoli GFM, Johnson DW, Yang WL, et al. Immunosuppression therapy for idiopathic membranous nephropathy: systematic review with network meta-analysis. J Nephrol. 2022;35(4):1159\u201370.","journal-title":"J Nephrol"},{"issue":"11","key":"2944_CR68","volume":"11","author":"TC von Groote","year":"2021","unstructured":"von Groote TC, Williams G, Au EH, Chen Y, Mathew AT, Hodson EM, et al. Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome. Cochrane Database Syst Rev. 2021;11(11):CD004293.","journal-title":"Cochrane Database Syst Rev"},{"key":"2944_CR69","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","volume":"100","author":"KDIGO Glomerular Diseases Work Group","year":"2021","unstructured":"KDIGO Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases: executive summary. Kidney Int. 2021;100:753\u201379.","journal-title":"Kidney Int"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-026-02944-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-026-02944-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-026-02944-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T12:02:30Z","timestamp":1789819350000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-026-02944-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,19]]},"references-count":69,"alternative-id":["2944"],"URL":"https:\/\/doi.org\/10.1007\/s10157-026-02944-4","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,19]]},"assertion":[{"value":"20 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"HN has received grants from the Japan Society for the Promotion of Science (JSPS KAKENHI; Grant Numbers 24K06239, 18K10828, and 19K3092) and lecture fees from Kissei Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., and Astellas Pharma Inc. YT has received grants from JSPS KAKENHI (25K13447) and lecture fees as well as travel support for meeting attendance from Cochrane Japan. TS has received lecture fees from AstraZeneca K.K., Kyowa Kirin Co., Ltd., Mitsubishi Tanabe Pharma Corporation, and Astellas Pharma Inc. NK has received consulting fees from GlaxoSmithKline K.K. and Kyowa Kirin Co., Ltd., and lecture fees from Eisai Co., Ltd., Taisho Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Vantive Co., Ltd., GlaxoSmithKline K.K., Takeda Pharmaceutical Company Limited, and Kissei Pharmaceutical Co., Ltd. SS has received lecture fees from AstraZeneca K.K. TW has received grants from JSPS KAKENHI (Grant Number 25K11556) and lecture fees from AstraZeneca K.K. and Kyowa Kirin Co., Ltd. All other authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was a systematic review and NMA based exclusively on data from previously published studies. No new individual patient data were collected, and no interventions were performed as part of this research. Therefore, in accordance with Japanese ethical guidelines and applicable regulations, institutional review board approval and informed consent were not required.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}